{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:23:11Z","timestamp":1792002191401,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Center for Blood Research, University of British Columbia"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.leukres.2018.02.005","type":"journal-article","created":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T17:12:21Z","timestamp":1518282741000},"page":"75-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy"],"prefix":"10.1016","volume":"67","author":[{"given":"Colleen A.C.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon A.Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Leitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.leukres.2018.02.005_bib0005","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.mayocp.2015.04.001","article-title":"Myelodysplastic syndromes: diagnosis and treatment","volume":"90","author":"Steensma","year":"2015","journal-title":"Mayo Clin. Proc."},{"issue":"June (2)","key":"10.1016\/j.leukres.2018.02.005_bib0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2018.02.005_bib0015","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.005_bib0020","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.leukres.2017.02.008","article-title":"New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): characteristics of refined MDS types","volume":"57","author":"Strupp","year":"2017","journal-title":"Leuk. Res."},{"issue":"March (6)","key":"10.1016\/j.leukres.2018.02.005_bib0025","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"September (12)","key":"10.1016\/j.leukres.2018.02.005_bib0030","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.005_bib0035","series-title":"MDS Clear Path","author":"Wells","year":"2013"},{"issue":"January (1)","key":"10.1016\/j.leukres.2018.02.005_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-010-1091-1","article-title":"Iron overload in MDS-pathophysiology, diagnosis, and complications","volume":"90","author":"Gattermann","year":"2011","journal-title":"Ann. Hematol."},{"issue":"September (9)","key":"10.1016\/j.leukres.2018.02.005_bib0045","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3324\/haematol.2011.048546","article-title":"Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes","volume":"97","author":"Gattermann","year":"2012","journal-title":"Haematologica"},{"issue":"June (6)","key":"10.1016\/j.leukres.2018.02.005_bib0050","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ejh.12300","article-title":"Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)","volume":"92","author":"Angelucci","year":"2014","journal-title":"Eur. J. Haematol."},{"issue":"January (2)","key":"10.1016\/j.leukres.2018.02.005_bib0055","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00277-012-1594-z","article-title":"Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload","volume":"92","author":"Nolte","year":"2013","journal-title":"Ann. Hematol."},{"issue":"July (2)","key":"10.1016\/j.leukres.2018.02.005_bib0060","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2018.02.005_bib0065","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12185-008-0118-z","article-title":"Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload","volume":"88","author":"Gattermann","year":"2008","journal-title":"Int. J. Hematol."},{"issue":"November (11)","key":"10.1016\/j.leukres.2018.02.005_bib0070","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.21269","article-title":"Consensus statement on iron overload in myelodysplastic syndromes","volume":"83","author":"Bennett","year":"2008","journal-title":"Am. J. Hematol."},{"issue":"June (17)","key":"10.1016\/j.leukres.2018.02.005_bib0075","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1200\/JCO.2010.34.1222","article-title":"Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome","volume":"30","author":"List","year":"2012","journal-title":"Journal Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2018.02.005_bib0080","first-page":"1588","article-title":"Predicting survival and leukemic evolution in patients with myelodysplastic syndrome","volume":"91","author":"Malcovati","year":"2006","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.leukres.2018.02.005_bib0085","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1182\/blood.V118.21.2775.2775","article-title":"Transfusion-dependency is the most important prognostic factor for survival in 1000 newly diagnosed MDS pateints with low- and intermediate-1 risk MDS in the european LeukemiaNet MDS registry","volume":"118","author":"De Swart","year":"2011","journal-title":"Blood"},{"issue":"October (30)","key":"10.1016\/j.leukres.2018.02.005_bib0090","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making","volume":"23","author":"Malcovati","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"June (10)","key":"10.1016\/j.leukres.2018.02.005_bib0095","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1200\/JCO.2009.25.2395","article-title":"Incidence and clinical complications of myelodysplastic syndromes among United States medicare beneficiaries","volume":"28","author":"Goldberg","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"August (3)","key":"10.1016\/j.leukres.2018.02.005_bib0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3816\/CLK.2008.n.026","article-title":"Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy","volume":"2","author":"Leitch","year":"2008","journal-title":"Clin. Leuk."},{"issue":"7","key":"10.1016\/j.leukres.2018.02.005_bib0105","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.leukres.2009.12.004","article-title":"Does iron chelation therapy improve suvival in regularly transfused lower risk MDS patients? A multicenter study by the GFM","volume":"34","author":"Rose","year":"2010","journal-title":"Leuk. Res."},{"issue":"August (8)","key":"10.1016\/j.leukres.2018.02.005_bib0110","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.leukres.2012.04.006","article-title":"Improved survival in MDS patients receiving iron chelation therapy \u2013 a matched pair analysis of 188 patients from the Dusseldorf MDS registry","volume":"36","author":"Neukirchen","year":"2012","journal-title":"Leuk. Res."},{"issue":"August (4)","key":"10.1016\/j.leukres.2018.02.005_bib0115","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2217\/cer.15.20","article-title":"Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes","volume":"4","author":"Zeidan","year":"2015","journal-title":"J. Comp. Eff. Res."},{"issue":"May","key":"10.1016\/j.leukres.2018.02.005_bib0120","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.leukres.2017.01.033","article-title":"Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: registry analysis at 5 years","volume":"56","author":"Lyons","year":"2017","journal-title":"Leuk. Res."},{"issue":"21","key":"10.1016\/j.leukres.2018.02.005_bib0125","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V118.21.2776.2776","article-title":"Impact of iron chelation therapy on overall survival and AML transformation in lower risk MDS patients treated at the Moffitt Cancer Center","volume":"118","author":"Komrokji","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2018.02.005_bib0130","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.leukres.2014.02.003","article-title":"Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes","volume":"38","author":"Delforge","year":"2014","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.leukres.2018.02.005_bib0135","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00277-014-2274-y","article-title":"Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications","volume":"94","author":"Remacha","year":"2015","journal-title":"Ann. Hematol."},{"issue":"December (5)","key":"10.1016\/j.leukres.2018.02.005_bib0140","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjh.13053","article-title":"The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome","volume":"167","author":"Mainous","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.02.005_bib0145","first-page":"130","article-title":"Impact of treatment with iron chelation therapy in lower-risk MDS patients participating in the European Leukemianet MDS (EUMDS) registry","author":"Hoeks","year":"2017","journal-title":"Blood"},{"issue":"May","key":"10.1016\/j.leukres.2018.02.005_bib0150","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.critrevonc.2017.03.002","article-title":"Toxicity of iron overload and iron overload reduction in the setting of hematopoietic stem cell transplantation for hematologic malignancies","volume":"113","author":"Leitch","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.leukres.2018.02.005_bib0155","article-title":"Estimation of the relationship between serum ferritin and liver iron concentration in patients with myelodysplastic syndromes","author":"Gattermann","year":"2013","journal-title":"European Hematology Association Meeting"},{"issue":"21","key":"10.1016\/j.leukres.2018.02.005_bib0160","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V116.21.122.122","article-title":"Iron overload accelerates development of leukaemia: evidence from a mouse model","volume":"116","author":"Chan","year":"2010","journal-title":"Blood"},{"issue":"April (4)","key":"10.1016\/j.leukres.2018.02.005_bib0165","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(06)70437-6","article-title":"Infections and thalassaemia","volume":"6","author":"Vento","year":"2006","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.leukres.2018.02.005_bib0170","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0268-960X(95)90038-1","article-title":"Iron: mammalian defense systems, mechanisms of disease, and chelation therapy approaches","volume":"9","author":"Kontoghiorghes","year":"1995","journal-title":"Blood Rev."},{"issue":"August (1)","key":"10.1016\/j.leukres.2018.02.005_bib0175","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00042560-199808150-00009","article-title":"Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients","volume":"18","author":"Salhi","year":"1998","journal-title":"J. Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"issue":"September (1)","key":"10.1016\/j.leukres.2018.02.005_bib0180","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ajh.2830350104","article-title":"Desferrioxamine improves neutrophil phagocytosis in thalassemia major","volume":"35","author":"Cantinieaux","year":"1990","journal-title":"Am. J. Hematol."},{"issue":"July (1)","key":"10.1016\/j.leukres.2018.02.005_bib0185","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1600-0609.1987.tb00159.x","article-title":"Neutrophil dysfunctions in thalassaemia major: the role of cell iron overload","volume":"39","author":"Cantinieaux","year":"1987","journal-title":"Eur. J. Haematol."},{"issue":"April (4)","key":"10.1016\/j.leukres.2018.02.005_bib0190","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0022-2143(99)90066-5","article-title":"Ferritin-associated iron induces neutrophil dysfunction in hemosiderosis","volume":"133","author":"Cantinieaux","year":"1999","journal-title":"J. Lab. Clin. Med."},{"issue":"April (4)","key":"10.1016\/j.leukres.2018.02.005_bib0195","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10096-010-0875-5","article-title":"In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus","volume":"29","author":"Neupane","year":"2010","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis"},{"issue":"May (3)","key":"10.1016\/j.leukres.2018.02.005_bib0200","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0163-4453(84)93955-0","article-title":"Functional defects in phagocytic cells from patients with iron overload","volume":"8","author":"van Asbeck","year":"1984","journal-title":"J. Infect."},{"issue":"March (3)","key":"10.1016\/j.leukres.2018.02.005_bib0205","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V63.3.714.714","article-title":"Deferoxamine enhances phagocytic function of human polymorphonuclear leukocytes","volume":"63","author":"van Asbeck","year":"1984","journal-title":"Blood"},{"issue":"October (7)","key":"10.1016\/j.leukres.2018.02.005_bib0210","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1128\/IAI.00612-08","article-title":"Increased susceptibility to Mycobacterium avium in hemochromatosis protein HFE-deficient mice","volume":"76","author":"Gomes-Pereira","year":"2008","journal-title":"Infect. Immun."},{"issue":"October","key":"10.1016\/j.leukres.2018.02.005_bib0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijid.2015.09.001","article-title":"Severe bacterial infections in patients with non-transfusion-dependent thalassemia: prevalence and clinical risk factors","volume":"39","author":"Teawtrakul","year":"2015","journal-title":"Int. J. Infect. Dis."},{"issue":"August (8)","key":"10.1016\/j.leukres.2018.02.005_bib0220","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/j.1537-2995.2009.02186.x","article-title":"Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus","volume":"49","author":"Neupane","year":"2009","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.leukres.2018.02.005_bib0225","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/asheducation-2011.1.250","article-title":"World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants","author":"Vardiman","year":"2011","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr."},{"issue":"6","key":"10.1016\/j.leukres.2018.02.005_bib0230","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"issue":"August (5)","key":"10.1016\/j.leukres.2018.02.005_bib0235","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1503\/cmaj.050051","article-title":"A global clinical measure of fitness and frailty in elderly people","volume":"175","author":"Rockwood","year":"2005","journal-title":"CMAJ"},{"issue":"July (1)","key":"10.1016\/j.leukres.2018.02.005_bib0240","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/bjh.14033","article-title":"Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study","volume":"174","author":"Buckstein","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.02.005_bib0245","series-title":"Special Authority Request, Deferiprone and Deferasirox Coverage, Initial and Renewal","author":"British Columbia Ministry of Health","year":"2016"},{"issue":"9","key":"10.1016\/j.leukres.2018.02.005_bib0250","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2010.03.009","article-title":"Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study","volume":"34","author":"Gattermann","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2018.02.005_bib0255","series-title":"Statistics Canada Life Expectancy, at Birth and at Age 65, by Sex and by Province And Territory","year":"2012"},{"issue":"3","key":"10.1016\/j.leukres.2018.02.005_bib0260","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0163-4453(84)93955-0","article-title":"Functional defects in phagocytic cells from patients with iron overload","volume":"8","author":"van Asbeck","year":"1984","journal-title":"J. Infect."},{"issue":"May (S 131)","key":"10.1016\/j.leukres.2018.02.005_bib0265","first-page":"240","article-title":"Haematopoietic improvement following iron chelation may result from deferasirox-induced restoration of T cell immune surveillance","volume":"37","author":"Opat","year":"2013","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.leukres.2018.02.005_bib0270","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00277-017-2985-y","article-title":"Reactive oxygen species mediated T lymphocyte abnormalities in an iron-overloaded mouse model and iron-overloaded patients with myelodysplastic syndromes","volume":"96","author":"Chen","year":"2017","journal-title":"Ann. Hematol."},{"issue":"November","key":"10.1016\/j.leukres.2018.02.005_bib0275","first-page":"227","article-title":"Red blood cell transfusions shape macrophages towards an anti-inflammatory functional phenotype and impair the immune response to infectious cues","author":"Vinchi","year":"2017","journal-title":"Blood"},{"issue":"August (8)","key":"10.1016\/j.leukres.2018.02.005_bib0280","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ajh.21192","article-title":"Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts","volume":"83","author":"Chee","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.02.005_bib0285","series-title":"Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (TELESTO) ClinicalTrials.gov Identifier","year":"2016"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261830033X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261830033X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T03:38:52Z","timestamp":1719805132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261830033X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":57,"alternative-id":["S014521261830033X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.02.005","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}